Medicine for glaucoma could be used to treat TB, claim scientists

Image
ANI Washington
Last Updated : Jul 26 2015 | 11:22 AM IST

In a breakthrough discovery, the scientists have suggested that a common medication used to treat glaucoma could also be used to treat tuberculosis (TB).

Robert Abramovitch, a Michigan State University microbiologist, along with a graduate student discovered that ethoxzolamide, a sulfa-based compound found in many prescription glaucoma drugs, actually turns off the bacterium's ability to invade the immune system.

Abramovitch said that ethoxzolamide stops TB from deploying its weapons...shutting down its ability to grow inside certain white blood cells in the immune system and found that the compound reduces disease symptoms in mice.

Abramovitch added that the compound which they found inhibits TB's ability to detect acidic environments, effectively blindfolding the bacterium so it can't resist the immune system's assault.

Abramovitch and his team monitored 2,73,000 different compounds in the hope of finding one that could possibly stop the disease. By using a synthetic biosensor that glows green in response to conditions that mimic TB infection, something Abramovitch developed earlier in his research, he eventually found the needle in the haystack that turned the bacterium's sensing ability off.

Abramovitch suggested that it could help shorten the length of treatment and slow the emergence of drug resistance, particularly if found to work in conjunction with other existing TB drugs.

The study has been published in Antimicrobial Agents and Chemotherapy.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 26 2015 | 11:08 AM IST

Next Story